HBIO — Harvard Bioscience, Inc.

HBIO Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics:

• Revenue: $20.6 million, at the high end of guidance ($19 million to $21 million) but down from $22 million in Q3 2024.
• Gross Margin: 58.4%, improved from 58.1% in Q3 2024 and exceeded guidance (56% to 58%).
• Adjusted EBITDA: Increased to $2 million, up from $1.3 million in Q3 2024, driven by reduced operating expenses.
• Operating Cash Flow: Positive cash flow of $1.1 million for Q3, with year-to-date cash flow from operations at $6.8 million compared to a negative $0.3 million in the same period last year.
• Net Debt: Reduced to $27.5 million from $33.8 million at year-end 2024.

2. Strategic Updates and Business Highlights:

• CEO John Duke emphasized three priorities for 2025: maintaining financial discipline, accelerating product adoption, and strengthening capital structure through debt refinancing.
• Notable product developments include the successful rollout of the SoHo Telemetry and the launch of the Incub8 Multiwell System, which has received positive initial customer feedback.
• Expanded distribution agreement with Fisher Scientific to enhance market access.
• Backlog has reached its highest level in nearly two years, indicating increased demand across multiple product lines and regions.

3. Forward Guidance and Outlook:

• Q4 revenue guidance set between $22.5 million and $24.5 million, with expectations for continued sequential improvement in gross margin (58% to 60%).
• Anticipated risks include potential impacts from a prolonged U.S. government shutdown affecting NIH funding, which could delay orders into 2026.

4. Bad News, Challenges, or Points of Concern:

• Year-over-year revenue decline from Q3 2024 to Q3 2025, indicating challenges in maintaining growth.
• Flat orders in China and a significant year-over-year decline (19.6%) in revenue from that region, although recent trade talks provide some optimism.
• Dependence on NIH funding for academic customers, with uncertainty due to the government shutdown affecting visibility and order timing.

5. Notable Q&A Insights:

• Management noted a broad-based uptick in demand for telemetry products, not limited to specific regions or customer types.
• Backlog growth is attributed to a uniform increase across various geographies and products, with no single product disproportionately influencing it.
• Concerns were raised about the visibility of NIH funding among customers, with some lacking clear communication from the NIH due to the shutdown.
• ERP project completion is expected to yield benefits in operational efficiency and cost reduction, contributing to improved financial performance.

Overall, while Harvard Bioscience showed operational progress and improved financial metrics in Q3 2025, challenges remain, particularly regarding external funding sources and international market performance.